Justin Paget/DigitalVision via Getty Images Introduction Last year, I started covering Zoetis Inc. (NYSE:ZTS), the animal health-focused healthcare giant. My most recent article on this stock was written on January 10, when I went with the title "Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns." Here's a part of my takeaway back then: Despite economic uncertainties, the company anticipates continued success in key franchises, projecting double-digit operational growth for the companion anima ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Zoetis (ZTS) closed the most recent trading day at $165.69, moving -0.1% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 0.04%. Meanwhile, the Dow experienced a drop of 0.03%, and the technology-dominated Nasdaq saw an increase of 0.03%.Prior to today's trading, shares of the animal health company had lost 8.95% over the past month. This has lagged the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57% in that time.Market participants will be closel ...

FatCamera In my last article, I mentioned my desire to reduce (and potentially, eliminate) my exposure to bio-pharma companies. So, the fact that I’m writing a bullish piece on Zoetis Inc. (NYSE:ZTS) here might come as a surprise. But, in today’s report I’m going to discuss why I view Zoetis in a more positive light than other, better known, healthcare stocks such as Amgen (AMGN), Johnson and Johnson (JNJ), and Pfizer (PFE). Simply put, since spinning off from Pfizer, Zoetis has produced very unique com ...

FatCamera Introduction As you guys probably know, I like dividend growth investing. With dividend growth investing, you can compound your wealth in a sustainable way and if you invest in dividend growth stocks, the chances are high that you have exposure to high-quality and resilient companies. The composition of a dividend growth portfolio depends heavily on your time horizon, but if you have a lot of time on your side, it is a good idea to also buy some companies with high dividend growth rates. This brou ...

Particular financial metrics have been proven to indicate market-beating potential when analyzing stocks. Three examples are businesses with consistently growing dividend payments and a low payout ratio, steady share repurchases, and a high and rising return on invested capital. Finding companies that meet these requirements creates a "stocked pond" for us to fish in.One business swimming around in this stocked pond is animal health specialist Zoetis (ZTS 0.06%). It's achieved a total return above 500% sinc ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2024 Animal Health Summit on Thursday, February 29, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 11:40 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations ...

Zoetis, Inc. (ZTS) delivered fourth-quarter 2023 adjusted earnings (excluding one-time items) of $1.24 per share, which missed the Zacks Consensus Estimate of $1.33. In the year-ago quarter, the company delivered earnings of $1.15 per share.Total revenues grew 8% year over year to $2.21 billion, surpassing the Zacks Consensus Estimate of $2.19 billion in the reported quarter. Shares of Zoetis have gained 20.6% in the past year against the industry’s 2.8% decline.Image Source: Zacks Investment ResearchQuarte ...

Core Insights - Zoetis reported $2.21 billion in revenue for Q4 2023, an 8.5% year-over-year increase, with EPS of $1.24 compared to $1.15 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $2.19 billion by 1.04%, while EPS fell short of the consensus estimate of $1.33 by 6.77% [1] Revenue Performance - U.S. revenue reached $1.21 billion, surpassing the average estimate of $1.19 billion, reflecting an 8.9% year-over-year increase [2] - Livestock revenue in the U.S. was $270 million, exceeding the estimate of $248.25 million, marking a 4.3% increase year-over-year [2] - International revenue for Companion Animals was $507 million, slightly below the estimate of $510.84 million, but still showing a 12.7% year-over-year growth [2] - Total international revenue was $982 million, above the estimate of $971.31 million, representing a 9% year-over-year increase [2] Segment Performance - Companion Animal revenue totaled $1.45 billion, slightly below the estimate of $1.47 billion, with an 11.1% year-over-year increase [2] - Livestock revenue was $745 million, exceeding the estimate of $696.05 million, reflecting a 4.9% year-over-year increase [2] - Contract Manufacturing & Human Health revenue was $20 million, below the estimate of $25.39 million, showing a significant decline of 25.9% year-over-year [2] - Poultry revenue within Livestock was $127 million, surpassing the estimate of $119.46 million, with a 10.4% year-over-year increase [2] - Companion Animal revenue from Horses was $88 million, exceeding the estimate of $55.62 million, marking an 11.4% year-over-year increase [2] - Revenue from Dogs and Cats was $1.36 billion, below the estimate of $1.44 billion, with an 11.1% year-over-year increase [2] - Swine revenue was $139 million, slightly above the estimate of $132.59 million, reflecting a 0.7% year-over-year increase [2] - Cattle revenue was $401 million, exceeding the estimate of $346.82 million, representing a 6.4% year-over-year increase [2] Stock Performance - Over the past month, Zoetis shares returned -1.1%, while the Zacks S&P 500 composite increased by 5.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Fourth Quarter and Full Year 2023 Financial Results Forward-looking Non-GAAP Financial Statements Information This presentation contains forward-looking statements, which reflect the current views of We use non-GAAP* financial measures, such as adjusted net income, adjusted diluted Zoetis with respect to: business plans or prospects, future operating or financial earnings per share and operational results (which exclude the impact of foreign exchange), performance, future guidance, future operating models; ...